Moderna Inc (MRNA) 13F Positioning & Ownership Changes (Q2 2026)

MRNA ranks #634 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

MRNA is a disclosed holding of Baillie Gifford (Baillie Gifford & Co.), one of the tracked superinvestors on AlphaSMO — it makes up 1.2% of that fund's own 13F portfolio.

MRNA is a top-conviction position for Theleme Partners LLP — at 33.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in MRNA belongs to FMR LLC, but the position matters far more to Theleme Partners LLP, who has 33.5% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Banque Pictet & Cie SA has added to its MRNA position for two straight quarters, increasing it by $274.6M to reach $414.3M today.

MRNA is up 4.8% today, and institutions have been net buyers of $1.8B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

MRNA reported a net loss of $3.2B over the trailing twelve months.

• Not yet profitable — net loss of $3.2B over the trailing twelve months
• Revenue declined 27.6% year over year
• Net income declined year over year, from -$2.9B to -$3.2B
• Operating cash flow was negative, using $1.9B in cash
• Current ratio of 3.29x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.43x equity — within a conventional range